PMC

Summary of assay protocol using F-PDOs and 96- or 384-well microplates. Scale bar, 200 µm. F-PDO, Fukushima patients-derived organoid; ATP, 5′ adenosine triphosphate.

In vivo xenograft growth of F-PDOs. (A) Tumor growth in F-PDO-bearing mice. (B) HE staining of tumor sections. The HE-stained images were captured using a ×40 objective. Scale bar, 50 µm. HE, hematoxylin and eosin; F-PDO, Fukushima patient-derived organoid.

Gene expression profiles of F-PDOs, endometrial tumors and endometrial cancer cell lines. Expression values (subtracted log ratios) are represented by color gradients. Red and blue colors indicate high and low expression, respectively. White indicates a log ratio of 0. F-PDO, Fukushima patient-derived organoid.

High-throughput assay of anticancer agents using Fukushima patient-derived organoid in 384-well plates. The bar graphs represent the area under the curve values calculated from the growth inhibition assay, using 61 anticancer agents at a range of 0.1–20 µM. The data represent the mean of triplicate experiments.

Phase-contrast and HE-stained images of the Fukushima patient-derived organoids and their source tumors. Phase-contrast images of (A) REME9, (B) REME11 and (C) REME16 were obtained using a ×10 objective. HE-stained images of the organoids (D) REME9, (E) REME11 and (F) REME16, and the source tumors of (G) REME9, (H) REME11 and (I) REME16, were viewed using a ×40 objective. The source tumor of the REME16 line was not ascites; it was a peritoneal metastasis from an endometrial tumor. Scale bars: Phase-contrast images, 200 µm; HE-stained images, 50 µm. HE, hematoxylin and eosin.

Response of F-PDOs to clinically used chemotherapeutics. (A) Dose-response curve of F-PDOs to anticancer agents. The F-PDOs were minced, seeded in 96-well plates, and treated with nine different concentrations (between 10 µM and 1.5 nM) of paclitaxel, carboplatin or mitomycin C for 6 days. The data represent the mean ± standard deviation of triplicate experiments. (B) Caspase-3/7 levels in F-PDOs treated with paclitaxel, carboplatin or mitomycin C. The time course quantification of caspase-3/7 fluorescence in F-PDOs treated with 10 µM each agent is presented. The graphs represent the time-course of fluorescence intensities, representing caspase-3/7 activity, between 6 and 144 h post-drug treatment. The data represent the mean ± standard deviation of triplicate experiments. For each F-PDO, images were captured at 0 h or the time when the fluorescence intensity reached its maximum following the drug treatment, as indicated by the arrows. Scale bar, 400 µm. F-PDO, Fukushima patient-derived organoid.